deltatrials

Gastric cancer Trials in Beijing, China

Conditions / Gastric cancer / Beijing, China

Gastric cancer has been the subject of sustained clinical investigation across multiple research sites.

163 total trials for this combination

Showing top 10 of 163 trials

Trials

NCT ID Title Status Phase
NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. ACTIVE_NOT_RECRUITING PHASE3
NCT05253053 To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors COMPLETED PHASE1/PHASE2
NCT06614751 A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway NOT_YET_RECRUITING PHASE1
NCT04276493 Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab COMPLETED PHASE1/PHASE2
NCT06710132 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) RECRUITING
NCT06363123 Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis RECRUITING
NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors RECRUITING
NCT07431281 Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 RECRUITING PHASE3
NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies ACTIVE_NOT_RECRUITING PHASE1/PHASE2
NCT06257264 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors RECRUITING

Related Pages